产品封面图

pCDF1-MCS2-EF1-copGFP载体

收藏
  • ¥1800
  • ZYbscience
  • 中国/美国
  • ZY111B-1
  • 2025年07月11日
    avatar
    上海泽叶生物科技有限公司
    11 年钻石会员

  • 企业认证

    点击 QQ 联系

    • 相关产品推荐更多 >

    万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 文献和实验
    • 技术资料
    • 保存条件：

      -20℃低温保存

    • 保质期：

      三年

    • 英文名：

      pCDF1-MCS2-EF1-copGFP

    • 库存：

      20

    • 供应商：

      泽叶生物

    载体基本信息

    出品公司: ZYbscience
    载体名称: pCDF1-MCS2-EF1-copGFP
    质粒类型: 慢病毒表达载体；cDNA表达载体
    克隆方法: 多克隆位点，限制性内切酶
    启动子: CMV
    载体大小: 6771 bp
    5' 测序引物及序列: LNCX-F AGCTCGTTTAGTGAACCGTCAGATC
    3' 测序引物及序列: EF1a-R
    载体标签: 无
    载体抗性: 氨苄青霉素（Ampicillin）
    筛选标记: GFP
    克隆菌株: stbl3 或者E. coli(RecA-)：OmniMAX 2
    宿主细胞（系）: 常用细胞系(e.g.HeLa, HEK293, HT1080, H1299)
    备注: pCDF1-MCS2-EF1-copGFP慢病毒表达载体是基于FIV的慢病毒载体；
    用于cDNA表达和克隆；高效转染细胞，建立稳定细胞系，表达水平高；
    产品目录号: ZY111B-1
    稳定性: 稳表达
    组成型/诱导型: 组成型
    病毒/非病毒: 慢病毒（FIV)

    载体质粒图谱和多克隆位点信息

    pCDF1-MCS2-EF1-copGFP 载体图谱
    pCDF1-MCS2-EF1-copGFP 多克隆位点

    pCDF1-MCS2-EF1-copGFP 载体特征

    载体简介

    背景简介：
A. Purpose of this Manual
This manual provides details and information necessary to generate expression constructs of your gene of interest in the pCDF lentivectors. Specifically, it provides critical instructions on amplification and cloning the cDNA into the pCDF Vectors, and verifying final expression constructs. This manual does not include information on packaging the pCDF expression constructs into pseudotyped viral particles or transducing your target cells of choice with these particles. 

B. Advantages of the Lentivector Expression System Lentiviral expression vectors are the most effective vehicles for delivering and expression of a gene of interest to almost any mammalian cell—including non-dividing cells and model organisms (C.A. Machida, 2003; M. Federico, 2003; W. C. Heiser, 2004). As with standard plasmid vectors, it is possible to introduce lentivector expression constructs in plasmid form into the cells with low-tomedium efficiency using conventional transfection protocols.
However, by packaging the lentivector construct into viral particles, you can obtain highly efficient transduction of expression constructs—even with the most difficult to transfect cells, such as primary, stem, and differentiated cells. The expression construct transduced in target cells is integrated into genomic DNA and provides stable, long-term expression of the target gene.
The lentiviral cDNA expression system consists of three main components:
(1) The lentiviral expression vector (e.g., pCDF1-MCS2-EF1-Puro)
(2) The lentiviral packaging plasmids (e.g., pPACKF1 Packaging Plasmid mix)
(3) A pseudoviral particle producer cell line (e.g., 293TN cells) 

The expression lentivector contains the genetic elements responsible for packaging, transduction, stable integration of the viral expression construct into genomic DNA, and expression of the target gene sequence. The packaging vector provides all the proteins essential for transcription and packaging of an RNA copy of the expression construct into recombinant viral particles. To produce a high titer of viral particles, expression and packaging vectors are transiently cotransfected into producer mammalian cells (e.g., HEK 293 cells). For a detailed description of SBI’s Lentivector expression system, please refer to the Lentivector Expression Systems user manual.
SBI’s novel pCDF Vectors are derived from feline immunodeficiency virus (FIV; Poeschla, 2003; for Safety Guidelines when working with these vectors, see section G). These pCDF Vectors, developed at SBI, are self-inactivating as a result of a deletion in the U3 region of 3’ ΔLTR (see Appendix for Vector Features). Upon integration into the genome, the 5’ LTR promoter is inactivated, which prevents formation of replication-competent viral particles.
When expressed, the hybrid CMV/FIV 5’ LTR drives high level transcription of the viral construct and produces a transcript that contains all the necessary functional elements (i.e., Psi, RRE, and cPPT) for efficient packaging. When this construct is expressed in HEK 293 cells that also express viral coat proteins (i.e., a packaging cell line), the pCDF transcripts are efficiently packaged into pseudoviral particles. After isolation, these pseudoviral particles containing the RNA version of the pCDF expression cassette can be efficiently transduced into any mammalian target cells. Following transduction into the target cells, this expression cassette is reverse transcribed and integrated into the genome of the target cell. The pCDF Vectors also contain a bacterial origin of replication and ampicillin resistance (AmpR) gene for propagation and selection in E.coli. 

The pCDF1-MCS2-EF1-Puro Vector (Cat. # CD110B-1) contains a puromycin resistance gene, under the control of a constitutive EF1 promoter and a WPRE regulatory element, to enable selection of target cells stably expressing the cDNA template. The pCDF1-MCS2-EF1-copGFP Vector (Cat. # CD111B-1) contains a copGFP gene under the control of a EF1 promoter and WPRE element. CopGFP is a novel fluorescent protein ,derived from copepod plankton (Panalina sp.), which is similar to EGFP but has a brighter color This gene serves as a reporter for the transfected or transduced cells. 

pCDF Cloning and Expression Lentivectors
The FIV derived pCDF vectors contain the following features:
 CMV promoter—promotes a high level of expression of your gene of interest in a wide variety of cell lines.
 Multiple Cloning Site (MCS)—for cloning the gene of interest in MCS located downstream of CMV promoter.
 WPRE element—enhances stability and translation of the CMVdriven transcripts.
 SV40 polyadenylation signal—enables efficient termination of transcription and processing of recombinant transcripts. 
Optional second expression cassette—provides expression of puromycin resistance gene or copGFP reporter under control of constitutive elongation factor 1 (EF1) promoter for selection or FACS analysis of transduced cells.
 Hybrid CMV-5LTR promoter—provides a high level of expression of the full-length viral transcript in producer 293 cells.
 Genetic elements (cPPT, GAG, LTRs)—necessary for packaging, transducing, and stably integrating the viral expression construct into genomic DNA.
 SV40 origin—for stable propagation of the pCDF plasmid in mammalian cells.
 pUC origin—for high copy replication and maintenance of the plasmid in E.coli cells.
 Ampicillin resistance gene—for selection in E.coli cells.

    载体序列

    LOCUS       pCDF1-MCS2-EF1-copGFP	6771 bp 	DNA	SYN
DEFINITION  pCDF1-MCS2-EF1-copGFP
ACCESSION   
KEYWORDS    
SOURCE      
  ORGANISM  other sequences; artificial sequences; vectors.
FEATURES             Location/Qualifiers
     source          1..6771
                     /organism="pCDF1-MCS2-EF1-copGFP"
                     /mol_type="other DNA"
     misc_feature    287..307
                     /label="CMV_fwd_primer"
     misc_feature    1165..1180
                     /label="cPPT"
     misc_feature    1633..1653
                     /label="CMV_fwd_primer"
     promoter        1634..1703
                     /label="CMV_promoter"
     misc_feature    1677..1696
                     /label="pCEP_fwd_primer"
     misc_feature    1679..1703
                     /label="LNCX_primer"
     CDS             2366..3124
                     /label="ORF frame 2"
                     /translation="MESDESGLPAMEIECRITGTLNGVEFELVGGGEGTPKQGRMTNK
                     MKSTKGALTFSPYLLSHVMGYGFYHFGTYPSGYENPFLHAINNGGYTNTRIEKYEDGG
                     VLHVSFSYRYEAGRVIGDFKVVGTGFPEDSVIFTDKIIRSNATVEHLHPMGDNVLVGS
                     FARTFSLRDGGYYSFVVDSHMHFKSAIHPSILQNGGPMFAFRRVEELHSNTELGIVEY
                     QHAFKTPIAFARSRAQSSNSAVDGTAGPGSTGSR*"
     misc_feature    3133..3708
                     /label="WPRE"
                     /translation="MESDESGLPAMEIECRITGTLNGVEFELVGGGEGTPKQGRMTNK
                     MKSTKGALTFSPYLLSHVMGYGFYHFGTYPSGYENPFLHAINNGGYTNTRIEKYEDGG
                     VLHVSFSYRYEAGRVIGDFKVVGTGFPEDSVIFTDKIIRSNATVEHLHPMGDNVLVGS
                     FARTFSLRDGGYYSFVVDSHMHFKSAIHPSILQNGGPMFAFRRVEELHSNTELGIVEY
                     QHAFKTPIAFARSRAQSSNSAVDGTAGPGSTGSR*"
     CDS             3221..3961
                     /label="ORF frame 2"
                     /translation="MPLYHAIASRMAFIFSSLYKSWLLSLYEELWPVVRQRGVVCTVF
                     ADATPTGWGIATTCQLLSGTFAFPLPIATAELIAACLARCWTGARLLGTDNSVVLSGK
                     SSSFPWLLACVATWILRGTSFCYVPSALNPADLPSRGLLPALRPLPRLRLRPQTSRIS
                     LWAASPPVPMTELEDRFRKLFGTTSTTGDSTVDSEDEPPKKEKRVDWDEYWNPEIDSF
                     QCFVKLRGVSLLRTFEFSLEAPTDTINI*"
     CDS             3234..3731
                     /label="ORF frame 3"
                     /translation="MLLLPVWLSFSPPCINPGCCLFMRSCGPLSGNVAWCALCLLTQP
                     PLVGALPPPVSSFPGLSLSPSLLPRRNSSPPALPAAGQGLGCWALTIPWCCRGNHRPF
                     LGCSPVLPPGFCAGRPSATSLRPSIQRTFLPAACCRLCGLFRVFAFALRRVGSPFGPP
                     PRRYR*"
     misc_feature    3818..3843
                     /label="U3PPT"
                     /translation="MLLLPVWLSFSPPCINPGCCLFMRSCGPLSGNVAWCALCLLTQP
                     PLVGALPPPVSSFPGLSLSPSLLPRRNSSPPALPAAGQGLGCWALTIPWCCRGNHRPF
                     LGCSPVLPPGFCAGRPSATSLRPSIQRTFLPAACCRLCGLFRVFAFALRRVGSPFGPP
                     PRRYR*"
     misc_feature    3820..3843
                     /label="U3PPT"
                     /translation="MLLLPVWLSFSPPCINPGCCLFMRSCGPLSGNVAWCALCLLTQP
                     PLVGALPPPVSSFPGLSLSPSLLPRRNSSPPALPAAGQGLGCWALTIPWCCRGNHRPF
                     LGCSPVLPPGFCAGRPSATSLRPSIQRTFLPAACCRLCGLFRVFAFALRRVGSPFGPP
                     PRRYR*"
     terminator      4058..4177
                     /label="SV40_PA_terminator"
                     /translation="MLLLPVWLSFSPPCINPGCCLFMRSCGPLSGNVAWCALCLLTQP
                     PLVGALPPPVSSFPGLSLSPSLLPRRNSSPPALPAAGQGLGCWALTIPWCCRGNHRPF
                     LGCSPVLPPGFCAGRPSATSLRPSIQRTFLPAACCRLCGLFRVFAFALRRVGSPFGPP
                     PRRYR*"
     misc_feature    4146..4165
                     /label="EBV_rev_primer"
                     /translation="MLLLPVWLSFSPPCINPGCCLFMRSCGPLSGNVAWCALCLLTQP
                     PLVGALPPPVSSFPGLSLSPSLLPRRNSSPPALPAAGQGLGCWALTIPWCCRGNHRPF
                     LGCSPVLPPGFCAGRPSATSLRPSIQRTFLPAACCRLCGLFRVFAFALRRVGSPFGPP
                     PRRYR*"
     rep_origin      4195..4272
                     /label="SV40_origin"
                     /translation="MLLLPVWLSFSPPCINPGCCLFMRSCGPLSGNVAWCALCLLTQP
                     PLVGALPPPVSSFPGLSLSPSLLPRRNSSPPALPAAGQGLGCWALTIPWCCRGNHRPF
                     LGCSPVLPPGFCAGRPSATSLRPSIQRTFLPAACCRLCGLFRVFAFALRRVGSPFGPP
                     PRRYR*"
     misc_feature    4257..4276
                     /label="SV40pro_F_primer"
                     /translation="MLLLPVWLSFSPPCINPGCCLFMRSCGPLSGNVAWCALCLLTQP
                     PLVGALPPPVSSFPGLSLSPSLLPRRNSSPPALPAAGQGLGCWALTIPWCCRGNHRPF
                     LGCSPVLPPGFCAGRPSATSLRPSIQRTFLPAACCRLCGLFRVFAFALRRVGSPFGPP
                     PRRYR*"
     promoter        complement(4364..4382)
                     /label="M13_reverse_primer"
                     /translation="MLLLPVWLSFSPPCINPGCCLFMRSCGPLSGNVAWCALCLLTQP
                     PLVGALPPPVSSFPGLSLSPSLLPRRNSSPPALPAAGQGLGCWALTIPWCCRGNHRPF
                     LGCSPVLPPGFCAGRPSATSLRPSIQRTFLPAACCRLCGLFRVFAFALRRVGSPFGPP
                     PRRYR*"
     misc_feature    complement(4381..4403)
                     /label="M13_pUC_rev_primer"
                     /translation="MLLLPVWLSFSPPCINPGCCLFMRSCGPLSGNVAWCALCLLTQP
                     PLVGALPPPVSSFPGLSLSPSLLPRRNSSPPALPAAGQGLGCWALTIPWCCRGNHRPF
                     LGCSPVLPPGFCAGRPSATSLRPSIQRTFLPAACCRLCGLFRVFAFALRRVGSPFGPP
                     PRRYR*"
     promoter        complement(4417..4446)
                     /label="lac_promoter"
                     /translation="MLLLPVWLSFSPPCINPGCCLFMRSCGPLSGNVAWCALCLLTQP
                     PLVGALPPPVSSFPGLSLSPSLLPRRNSSPPALPAAGQGLGCWALTIPWCCRGNHRPF
                     LGCSPVLPPGFCAGRPSATSLRPSIQRTFLPAACCRLCGLFRVFAFALRRVGSPFGPP
                     PRRYR*"
     gene            complement(5529..6389)
                     /label="Ampicillin"
                     /gene="Ampicillin"
                     /translation="MLLLPVWLSFSPPCINPGCCLFMRSCGPLSGNVAWCALCLLTQP
                     PLVGALPPPVSSFPGLSLSPSLLPRRNSSPPALPAAGQGLGCWALTIPWCCRGNHRPF
                     LGCSPVLPPGFCAGRPSATSLRPSIQRTFLPAACCRLCGLFRVFAFALRRVGSPFGPP
                     PRRYR*"
     CDS             complement(5529..6389)
                     /label="ORF frame 2"
                     /translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
                     IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
                     YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
                     DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
                     LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
                     EIGASLIKHW*"
     promoter        complement(6431..6459)
                     /label="AmpR_promoter"
                     /translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
                     IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
                     YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
                     DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
                     LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
                     EIGASLIKHW*"
     misc_feature    complement(6618..6640)
                     /label="pGEX_3_primer"
                     /translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
                     IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
                     YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
                     DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
                     LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
                     EIGASLIKHW*"
ORIGIN
    1 catatgccaa gtacgccccc tattgacgtc aatgacggta aatggcccgc ctggcattat
   61 gcccagtaca tgaccttatg ggactttcct acttggcagt acatctacgt attagtcatc
  121 gctattacca tggtgatgcg gttttggcag tacatcaatg ggcgtggata gcggtttgac
  181 tcacggggat ttccaagtct ccaccccatt gacgtcaatg ggagtttgtt ttggcaccaa
  241 aatcaacggg actttccaaa atgtcgtaac aactccgccc cattgacgca aatgggcggt
  301 aggcgtgtac ggtgggaggt ctatataagc agagcttgtg aaacttcgag gagtctcttt
  361 gttgaggact tttgagttct cccttgaggc tcccacagat acaataaata tttgagattg
  421 aaccctgtcg agtatctgtg taatcttttt tacctgtgag gtctcggaat ccgggccgag
  481 aacttcgcag ttggcgcccg aacagggact tgattgagag tgattgagga agtgaagcta
  541 gagcaataga aagctgttaa gcagaactcc tgctgaccta aatagggaag cagtagcaga
  601 cgctgctaac agtgagtatc tctagtgaag cagactcgag ctcataatca agtcattgtt
  661 taaaggccca gataaattac atctggtgac tcttcgcgga ccttcaagcc aggagattcg
  721 ccgagggaca gtcaacaagg taggagagat tctacagcaa catggggaat ggacaggggc
  781 gagattggaa aatggccatt aagagatgta gtaatgttgc tgtaggagta ggggggaaga
  841 gtaaaaaatt tggagaaggg aatttcagat gggccattag aatggctaat gtatctacag
  901 gacgagaacc tggtgatata ccagagactt tagatcaact aaggttggtt atttgcgatt
  961 tacaagaaag aagagaaaaa tttggatcta gcaaagaaat tgatatggca attcctgcat
 1021 tgaggagaaa tggtaggcaa tgtggcatgt ctgaaaaaga ggaggaatga tgaagtatct
 1081 cagacttatt ttataaggga gatactgtgc tgagttcttc cctttgagga aggtatgtca
 1141 tatcctagac atagtctcaa ttttaaaaga agaggtagga taggagggat ggccccttat
 1201 gaattattag cacaacaaga atccttaaga atacaagatt atttttctgc aataccacaa
 1261 aaattgcaag cacagtggat ttattataaa gatcaaaaag ataagaaatg gaaaggacca
 1321 atgagagtag aatactgggg acagggatca gtattattaa aggatgaaga gaagggatat
 1381 tttcttataa tcgatactag tattatgccc agtacatgac cttatgggac tttcctactt
 1441 ggcagtacat ctacgtatta gtcatcgcta ttaccatggt gatgcggttt tggcagtaca
 1501 tcaatgggcg tggatagcgg tttgactcac ggggatttcc aagtctccac cccattgacg
 1561 tcaatgggag tttgttttgg caccaaaatc aacgggactt tccaaaatgt cgtaacaact
 1621 ccgccccatt gacgcaaatg ggcggtaggc gtgtacggtg ggaggtctat ataagcagag
 1681 ctcgtttagt gaaccgtcag atcgcctgga gacgccatcc acgctgtttt gacctccata
 1741 gaagattcta gagcccgggc gcgccggatc cagatcttaa ttaatttaaa tgaattcgcg
 1801 gccgcgaagg atctgcgatc gctccggtgc ccgtcagtgg gcagagcgca catcgcccac
 1861 agtccccgag aagttggggg gaggggtcgg caattgaacg ggtgcctaga gaaggtggcg
 1921 cggggtaaac tgggaaagtg atgtcgtgta ctggctccgc ctttttcccg agggtggggg
 1981 agaaccgtat ataagtgcag tagtcgccgt gaacgttctt tttcgcaacg ggtttgccgc
 2041 cagaacacag ctgaagcttc gaggggctcg catctctcct tcacgcgccc gccgccctac
 2101 ctgaggccgc catccacgcc ggttgagtcg cgttctgccg cctcccgcct gtggtgcctc
 2161 ctgaactgcg tccgccgtct aggtaagttt aaagctcagg tcgagaccgg gcctttgtcc
 2221 ggcgctccct tggagcctac ctagactcag ccggctctcc acgctttgcc tgaccctgct
 2281 tgctcaactc tacgtctttg tttcgttttc tgttctgcgc cgttacagat ccaagctgtg
 2341 accggcgcct acgctagacg ccaccatgga gagcgacgag agcggcctgc ccgccatgga
 2401 gatcgagtgc cgcatcaccg gcaccctgaa cggcgtggag ttcgagctgg tgggcggcgg
 2461 agagggcacc cccaagcagg gccgcatgac caacaagatg aagagcacca aaggcgccct
 2521 gaccttcagc ccctacctgc tgagccacgt gatgggctac ggcttctacc acttcggcac
 2581 ctaccccagc ggctacgaga accccttcct gcacgccatc aacaacggcg gctacaccaa
 2641 cacccgcatc gagaagtacg aggacggcgg cgtgctgcac gtgagcttca gctaccgcta
 2701 cgaggccggc cgcgtgatcg gcgacttcaa ggtggtgggc accggcttcc ccgaggacag
 2761 cgtgatcttc accgacaaga tcatccgcag caacgccacc gtggagcacc tgcaccccat
 2821 gggcgataac gtgctggtgg gcagcttcgc ccgcaccttc agcctgcgcg acggcggcta
 2881 ctacagcttc gtggtggaca gccacatgca cttcaagagc gccatccacc ccagcatcct
 2941 gcagaacggg ggccccatgt tcgccttccg ccgcgtggag gagctgcaca gcaacaccga
 3001 gctgggcatc gtggagtacc agcacgcctt caagaccccc atcgccttcg ccagatcccg
 3061 cgctcagtcg tccaattctg ccgtggacgg caccgccgga cccggctcca ccggatctcg
 3121 ctaagtcgac aatcaacctc tggattacaa aatttgtgaa agattgactg gtattcttaa
 3181 ctatgttgct ccttttacgc tatgtggata cgctgcttta atgcctttgt atcatgctat
 3241 tgcttcccgt atggctttca ttttctcctc cttgtataaa tcctggttgc tgtctcttta
 3301 tgaggagttg tggcccgttg tcaggcaacg tggcgtggtg tgcactgtgt ttgctgacgc
 3361 aacccccact ggttggggca ttgccaccac ctgtcagctc ctttccggga ctttcgcttt
 3421 ccccctccct attgccacgg cggaactcat cgccgcctgc cttgcccgct gctggacagg
 3481 ggctcggctg ttgggcactg acaattccgt ggtgttgtcg gggaaatcat cgtcctttcc
 3541 ttggctgctc gcctgtgttg ccacctggat tctgcgcggg acgtccttct gctacgtccc
 3601 ttcggccctc aatccagcgg accttccttc ccgcggcctg ctgccggctc tgcggcctct
 3661 tccgcgtctt cgccttcgcc ctcagacgag tcggatctcc ctttgggccg cctccccgcc
 3721 ggtaccgatg acagagttag aagatcgctt caggaagcta tttggcacga cttctacaac
 3781 gggagacagc acagtagatt ctgaagatga acctcctaaa aaagaaaaaa gggtggactg
 3841 ggatgagtat tggaaccctg aaatcgatag cttccagtgc tttgtgaaac ttcgaggagt
 3901 ctctttgttg aggacttttg agttctccct tgaggctccc acagatacaa taaatatttg
 3961 agattgaacc ctgtcgagta tctgtgtaat cttttttacc tgtgaggtct cggaatccgg

    风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    相关实验

    • 【交流】载体构建时酶切位点选择及引物设计的相关问题

      CCC GAATTC TCAGTTAGCCTCCCCCAT -3'不知道我这个引物设计得合不合理呢？ 我还有疑问到底要不要去除终止子TGA啊？如果不去除对后面的copGFP表达有没有影响？如果要去除，对读码框的影响要不要考虑？ 我设计引物的时候没有去除终止密码子TGA，因为在copGFP前面还有一个EF1启动子驱动copGFP的表达，不知道我这样考虑对不对？附：

    • 【求助】VEGF和GFP融合蛋白

      naj2007 请教一下各位老师，在构建过表达载体的时候，VEGF和GFP是不是不可以做成融合蛋白，但是如果用不同的启动子的话，很容易丢失荧光，有没有什么解决方法。 zhujoker 可以做成融合蛋白的，即使是使用不同的启动子的话荧光也不那么容易丢失的，大不了你将荧光的启动子换成强的如CMV，EF1a之类。 kinguangjun 或者你可以用CMV-VEGF-IRES-GFP来做

    • 【公告】核酸技术版零应助贴整理2007.7.1-2007.7.30，请大家积极参与讨论，加分从优！

      ://www.dxy.cn/bbs/post/view?bid=64&id=9488616&sty=1&tpg=19&age=0 74. 【求助】哪位用过pCDF1-MCS1-EF1-copGFP ？ http://www.dxy.cn/bbs/post/view?bid=64&id=9495098&sty=1&tpg=18&age=0 75. 【求助】基因融合表达 http://www.dxy.cn/bbs/post/view?bid=64&id=9491568&sty=1&tpg=18&age

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    pCDF1-MCS2-EF1-copGFP载体
    ¥1000
    上海信裕生物科技有限公司
    2025年07月16日询价
    pCDF1-MCS2-EF1-copGFP载体
    ￥750
    上海盖宁生物科技有限公司
    2025年12月23日询价
    pCDF1-MCS2-EF1-copGFP载体
    ¥1000
    上海再康生物科技有限公司
    2025年11月20日询价
    pCDF1-MCS2-EF1-Puro载体
    ¥1800
    上海泽叶生物科技有限公司
    2025年07月13日询价
    载体pCDF1-MCS2-EF1-Puro
    ¥800
    上海沪震实业有限公司
    2025年07月12日询价
    pCDF1-MCS2-EF1-copGFP载体
    ¥1800